Ignite Creation Date:
2025-12-25 @ 5:02 AM
Ignite Modification Date:
2026-03-03 @ 2:19 PM
Study NCT ID:
NCT04891718
Status:
WITHDRAWN
Last Update Posted:
2022-07-08
First Post:
2021-05-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Sponsor:
Presage Biosciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumour | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | HNSCC | View |
| None | SCCHN | View |
| None | lymphoma | View |
| None | sarcoma | View |
| None | breast adenocarcinoma | View |
| None | melanoma | View |
| None | intratumoural microdosing | View |
| None | microdose injection | View |
| None | microdosing | View |
| None | in vivo oncology | View |
| None | in vivo drug sensitivity | View |
| None | tumour microenvironment | View |
| None | multiplexed immunohistochemistry | View |
| None | head and neck cancer | View |
| None | pharmacodynamic biomarkers | View |
| None | CIVO | View |
| None | master protocol | View |
| None | precision oncology | View |